Latest Breaking News On - Fibrosis progression - Page 1 : comparemela.com
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share:
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo
Avacopan safe and well tolerated in C3G patients
ChemoCentryx and VFMCRP plan to discuss registration pathway with regulatory agencies in US and EU
Conference call today at 4:30 pm Eastern Time